Additionally, network pharmacology and molecular docking studies reveal MA’s interactions with important targets related to lung cancer progression, such as EGFR and SRC, bolstering its potential as a novel anti-lung cancer agent. The gene discussed is EGFR; the disease is lung carcinoma.